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Summary Seven new anti-epileptic drugs (AEDs) have become available in Ireland
over the last 10 years; data from animal models and clinical trials suggest that they
have a superior safety proﬁle to older AEDs. A speciﬁc relationship between epilepsy
and psychiatric co-morbidity has long been recognised, including the relationship
between epilepsy and suicide.
AEDs are common agents taken in intentional drug overdoses.
We undertook a study to review the frequency and outcome of non-accidental over-
dose with seven new AEDS in an Irish population from 1996 to 2000. Method: All re-
ported cases of drug overdoses with AEDs from 1996 to 2000 were reviewed. Data
was provided by the National Poisons Information Centre, Beaumont Hospital and the
Central Statistics Ofﬁce. Medical records from Beaumont Hospital were reviewed in
speciﬁc cases of serious drug toxicities. An extensive review of published literature
reviewing the safety proﬁle of these AEDs was performed and medical literature re-
trieved from the databases of the pharmaceutical industry was similarly reviewed.
Results: Of the 164 reported cases of newer AEDs, there were no fatalities among the
cases followed up. Conclusion: The absence of mortalities and serious consequences
from deliberate self-poisoning with the newer agents is supportive evidence for the
superior safety proﬁle of the newer AEDs.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Over the last 10 years, seven new anti-epileptic
drugs (AEDs) have become available in Ireland.
These newer agents have a number of advantages
over older AEDs.1 Many have longer half lives, en-
abling once or twice daily dosing. They have a
reduced potential for drug interactions, and al-
though most of them undergo extensive hepatic
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metabolism (with the exception of levetiracetam,
gabapentin and vigabatrin), they are less likely to
cause hepatic enzyme induction, facilitating their
use as add-on agents and making polypharmacy
safer.2,3 Data from animal models and clinical tri-
als suggest that they have a safety proﬁle which is
superior to the older AEDs.
There are estimated to be up to 40,000 people
with epilepsy in Ireland, affecting 1 in 200 adults
and 1 in 100 children. This is comparable to the
prevalence ﬁgures world-wide, estimated at 5—10
per 1000.4 Epilepsy carries with it a mortality rate
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which is two to three times that of the general
population.5,6 While this excess is made up partly
by seizure-related accidental deaths7 (trauma,
drowning), sudden unexpected deaths in epilepsy8
(SUDEP) and death from underlying diseases (e.g.
strokes, infections of the central nervous sys-
tem), a recognised contribution comes from drug
intoxication.9—11
Gowers in 1901 was the ﬁrst to recognise and
document a speciﬁc association between epilepsy
and suicide.12 The association between epilepsy
and psychiatric co-morbidity is well recognised.
AEDs are relatively common agents taken in inten-
tional drug overdose.13 Hawton et al.14 looked at
the association between suicide and epilepsy over
a 2-year period (1976—1977). Eighty-four percent
of suicide attempts among patients with epilepsy
in this study involved self-poisoning, and in 65% of
these cases, AEDs were consumed. A 6-year ret-
rospective study by Manon-Espaillat et al.15 found
that suicide occurred in 18% of reported drug in-
toxications with AEDs between 1979 and 1985. The
incidence of suicide in patients with epilepsy as a
percentage of deaths in the same population was
averaged over 17 studies at 13.2%. More recent
ﬁgures suggest an incidence of 5—7%16 and male
patients with epilepsy are a particularly vulnerable
group.17 The prevalence of depression has been re-
ported as 60% in certain epilepsy populations.18,19
Mendez et al.20 reviewed the possible causative
factors for deliberate self-poisoning in epilepsy.
Across the cohort of patients who were hospi-
talised for suicide attempts by drug overdose,
when matched by age, sex and race, patients with
epilepsy had more borderline personality disorders
with multiple impulsive suicide attempts and psy-
chosis compared with patients without epilepsy.21
Patients with complex partial seizures were es-
pecially felt to be at high risk from attempted
suicide. A case control study evaluating a large co-
hort of patients in Sweden, found a high incidence
of psychiatric disease amongst the patients with
epilepsy who attempted suicide, with depression
being the most common diagnosis.22,23 In excess
of 81% of this group carried a diagnosis of inter-
current psychiatric disease. Hence, the safety of
anti-convulsants has signiﬁcant implications for
the management and prevention of mortality in
situations of non-accidental overdose.
In acute toxicity studies with gabapentin in mice
and rats, at maximum doses of 2000—8000mg/kg,
ataxia and laboured breathing were reported but
no deaths. With gabapentin, at doses exceeding
600mg, saturation of the carrier-mediated absorp-
tion pathway results in reduced bioavailability with
increasing doses.24 The mean lethal doses of lam-
otrigine in mice and rats have been established.25
Acute median oral lethal doses for mice were 202—
245 and 163—205mg/kg for rats. Animal studies
with levetiracetam demonstrated selective pro-
tection against induced seizures with a very high
safety margin for the drug in rodents.26 With oxcar-
bazepine, there is a low level of hepatic induction
of cytochrome P450 microsomal system.27
In acute toxicity studies across multiple species,
extremely high doses of oral oxcarbazepine were
tolerated and there were no compound-related
deaths. Animal studies with topiramate demon-
strated, there was no accumulation of the drug at
higher doses and there was no autoinduction or in-
hibition of enzymes that metabolise topiramate.28
The clinical development of vigabatrin was delayed
by the ﬁnding of microvacuolation in the white
matter of rodents and dogs.29 Since then however,
extensive studies have conﬁrmed that microvac-
uolation is species speciﬁc and does not occur in
humans.
Methods
We undertook a study to examine the frequency and
outcome of non-accidental overdose with seven
newer AEDs in an Irish population during the 5-year
period 1996—2000. A study of this nature has not
been undertaken in Ireland previously. This retro-
spective study was performed in the Department of
Neurology, Beaumont Hospital in collaboration with
the National Poisons Information Centre (NPIC),
Beaumont Hospital.
We reviewed data provided by the NPIC and the
Central Statistics Ofﬁce (CSO). The NPIC are con-
tacted by hospitals all around the country when
patients present to Accident and Emergency (A&E)
departments with deliberate self-poisoning. The
type of agent(s) and severity of the overdose re-
ported is noted by the NPIC and any potentially fa-
tal overdoses are followed up by the NPIC through
telephone contact with the relevant medical team
in Beaumont Hospital. The CSO keep a register
of all reported deaths due to AEDs. Deaths from
anti-convulsant agents other than phenytoin and
succinimides are represented within a single cate-
gory by the CSO, therefore it is not possible to dis-
tinguish mortalities from data between individual
AEDs.
In addition, we undertook an extensive litera-
ture review of established case reports of overdose
with the newer AEDs and the published literature
reviewing the general safety proﬁle of these drugs.
We were assisted by medical information from
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the pharmaceutical industry retrieved from their
databases, speciﬁcally addressing the safety pro-
ﬁle of these agents in situations of overdose. The
pharmaceutical industry had comprehensive data
for any potential fatalities from poisoning with the
newer AEDs from 1996 to 2000.
A comparative review was undertaken with the
older agents for the same time period.
Results
The total number of reported overdoses using any of
the seven newer AEDs over the 5-year period 1996—
2000 inclusive was 164. In addition there were three
reports from the United Kingdom and seven others
requesting information.
Themajority of overdoses involvedmore than one
agent (115 of 164 cases). There were no reported
mortalities among the cases reported from 1996 to
2000 (see Table 1). It was possible to conﬁrm this
through follow up information from both the NPIC
and the pharmaceutical industry data.
From 1996 to 2000, eight of the cases of delib-
erate self-poisoning recorded above were admit-
Table 1 Figures for non-accidental cases of overdose with the newer AEDs based on reports to the NPIC, Beaumont
Hospital.
Drug Year No. of reports Single/multiple
Gabapentin 1996 2 Both > 1 drug
1997 1 >1 drug
1998 11 7 cases > 1 drug
1999 7 4 cases > 1 drug
2000 12 10 cases > 1 drug
Lamotrigine 1996 8 6 cases > 1 drug
1997 18 11 cases > 1 drug
1998 17 13 cases > 1 drug
1999 28 17 cases > 1 drug
2000 26 16 cases > 1 drug
Levetiracetam 1996—1999 0
2000 1 >1 drug
Oxcarbazepine 1996—2000 0
Tiagabine 1996—1998 0
1999 2 >1 drug
2000 3 >1 drug
Topiramate 1996—1998 0
1999 1 >1 drug
2000 6 4 cases > 1 drug
Vigabatrin 1996 6 3 cases > 1 drug
1997 3 All > drug
1998 6 5 cases > 1 drug
1999 3 All > 1 drug
2000 3 All > 1 drug
ted and treated at Beaumont Hospital. Three pa-
tients overdosed with lamotrigine, three patients
with gabapentin and two patients with vigabatrin.
Representative brief case histories of their brief ad-
missions are as follows.
Case 1
An 18-year-old girl, with a background of epilepsy,
presented to the A&E department with convulsions.
Through collateral history, it was discovered that
she has ingested 45 tablets of lamotrigine and 20
tablets of penicillin in the previous 2 h. The precise
doses ingested are not known. She was treated with
activated charcoal and underwent cardiac monitor-
ing. She recovered on supportive therapy without
complication.
Case 2
A 21-year-old man presented to the A&E depart-
ment with drowsiness having taken an overdose
of his medications which consisted of sodium val-
proate, carbamazepine, thioridazine and gaba-
pentin. It was uncertain how many tablets he
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ingested in total. He was too drowsy for gastric
lavage or charcoal administration. He was mon-
itored closely and treated symptomatically and
subsequently made a complete recovery.
Case 3
A 22-year-old woman with a background history of
epilepsy, presented to the A&E department, admit-
ting to consuming unknown quantities of vigabatrin
and carbamazepine. She was asymptomatic at pre-
sentation and was treated with activated charcoal.
She remained asymptomatic and was discharged af-
ter overnight observation and psychiatric review.
Discussion
From review of published literature and medical in-
formation provided from the pharmaceutical indus-
try database, deliberate overdoses with the seven
newer agents are infrequent (see Table 2). Acute
life-threatening toxicity has not been observed to
date with gabapentin. Reduced absorption of the
drug at higher doses may limit drug bioavailability
at the time of overdosing, therefore reducing toxi-
city. Overdose with up to 49 g of gabapentin has re-
sulted in no serious consequences.24 With lamotrig-
ine, numerous case reports show recovery without
serious sequel for doses up to 4.5 g.30—32 However,
fatalities have been reported in cases of lamotrig-
ine poisoning. In a post-mortem case, where the dis-
tribution of lamotrigine was determined, the blood
concentration of lamotrigine was 52mg/l (thera-
peutic range of up to 14mg/l) with no other AEDs
detected. The precise cause of death in this case
was undetermined.33 Both gabapentin and lamot-
rigine confer an additional advantage in prescribing
Table 2 Case reports retrieved from pharmaceutical industry databases based on information submitted to the
AED manufacturers.
Drug Pharmaceutical industry data
Gabapentin Unpublished case reports submitted to manufacturer. Single published case report of ingestion
of 49 g with complete recovery following supportive treatment.24
Lamotrigine Overdoses up to 15 g have been reported. Numerous case reports published and unpublished
available. Fatalities reported from CNS and cardiovascular toxicity.
Levetiracetam No case reports.
Oxcarbazepine No case reports.
Tiagabine Numerous case reports including 23 cases published in a single study.35 No serious sequel
reported.
Topiramate Five cases of overdoses with doses ranging from 1.8 to 100 g. One unpublished case report
submitted to the manufacturer. All cases recovered without complication.
Vigabatrin Single published case report of overdosage.
Table 3 Total number of anti-convulsant overdoses
involving older agents reported to the NPIC between
1996 and 2000, excluding any cases involving the seven
newer anti-convulsants.
Name of drug Number of
reports to NPIC
1996—2000
Number of
cases with >1
drug involved
Carbamazepine 149 87
Clobazam 10 7
Ethosuximide 0 0
Phenobarbitone 35 16
Phenytoin 43 27
Sodium valproate 83 54
that they have both been reported to have mood
stabilising effects in patients.
There have been no case reports relating to
acute intoxication with either levetiracetam or ox-
carbazepine to date. There have been unpublished
reports of overdoses with topiramate, with over-
doses of up to 100 g of topiramate, without any re-
sulting fatality. A study reviewing 23 cases of over-
dose with tiagabine reported complete recovery in
all patients.34,35 There have been no case reports
relating to acute intoxication with either levetirac-
etam or oxcarbazepine and no reported fatalities
with vigabatrin in the published literature to date.
In our study, we found that despite the number
of patients who took overdoses of the newer AEDs,
whether in isolation or in combination with other
drugs, there were no fatalities seen amongst the
164 reported cases. The only other comparable pop-
ulation study in the literature was a Polish study,
which was conducted between 1990 and 1992 by
Miller et al., looking at suicide attempts reported
through their Poisons Control Centre.36 In the above
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Table 4 Number of overdoses with older AEDs admitted to Beaumont Hospital from 1996 to 2000.
Year Number of overdoses with older AEDs
admitted to Beaumont Hospital
Outcome of admissions
1996 1 Overnight admission.
1997 3 No fatalities. One overnight admission. Two
cases requiring hospitalisation for >1 week
and prolonged monitoring.
1998 3 No fatalities. One prolonged admission (>1 week).
1999 12 No fatalities. One prolonged admission (1 week).
2000 7 No fatalities. One prolonged admission (>1 week).
study, 9% of all patients treated for attempted sui-
cide carried a diagnosis of epilepsy.
The number of cases of non-accidental overdose
with the older anti-convulsants reported to the NPIC
between 1996 and 2000 is represented in Table 3.
The outcome of cases that were admitted solely
to Beaumont Hospital is represented in Table 4.
There were no fatalities amongst the 26 cases ad-
mitted. Five of these admissions, however were
prolonged hospital admissions lasting a minimum of
1 week, signifying more serious consequences from
drug toxicity.
There were 320 cases of poisoning with older
AEDs reported to the NPIC. The number of fa-
talities outside admissions to Beaumont Hospital
cannot be determined for the same time period.
There are, however, numerous case reports cit-
ing non-accidental overdoses and case reports
of fatalities with most of the older AEDs.37—39
Acute, life threatening fatalities have been re-
ported with phenobarbitone,37 sodium valproate,38
phenytoin39 and carbamazepine.40 This contrasts
with the paucity of fatalities from the newer AEDs.
Given the high incidence of impulsive suicidal
gestures reported among patients with epilepsy, es-
pecially partial epilepsy, as well as the high preva-
lence of depression, the newer generation AEDsmay
confer an additional advantage in prescribing. The
absence of serious consequences from deliberate
self-poisoning of these agents in our study is sup-
portive evidence for their superior safety proﬁle in
normal prescribing but also in the management and
prevention of fatality from the signiﬁcant risk of
non-accidental overdose of AEDs in individuals with
epilepsy.
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